ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

mitiglinide

Also written as “Mitiglinide”, “KAD-1229” and “mitiglinide and metformin”.

Its studies are mostly in Diabetes Mellitus, Type 2 · Diabetes Mellitus, led by 4 companies.

Drug pageMitiglinide: every studyAll 12 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since May 30, 20147 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Kissei Pharmaceuticalits history only30 open or runningphase 4since May 30, 2014Apr 17, 2007none ahead
JW Pharmaceuticalits history only20 open or runningphase 4since Apr 18, 2008Apr 18, 2008none ahead
Elixir Pharmaceuticalsits history only10 open or runningphase 3since Aug 20, 2007Aug 20, 2007none ahead
Orient Europharma10 open or runningphase 4since Mar 3, 2020Mar 3, 2020none ahead

Also a collaborator on its studies: Parexel.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Orient Europharma only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 3, 2020First study: phase 4 study in Diabetes Mellitus, Type 2First studyNCT04349696 · 16 enrolled · Taiwan

TargetBeta

“Sulfonylurea receptor 1, Kir6.2 blocker”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
repaglinideruleNovo Nordiskphase 432

Studies

The one study Orient Europharma leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT04349696Diabetes Mellitus, Type 2 · Taiwan4CompletedApr 201816

How it is read

Names in the registry

  • “Mitiglinide”, 4 entries
  • “KAD-1229”, 2 entries
  • “mitiglinide and metformin”, 2 entries
  • “mitiglinide”, 2 entries
  • “Mitiglinide calcium hydrate”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.